Phase III TIMES 2 trial of imeglimin shows positive results in type 2 diabetes.- Poxel/Sumitomo Dainippon Pharma
Related news and insights
New data from a mechanism of action study and new analyses of the global registration program for Eli Lilly and Company's Mounjaro (tirzepatide) injection were presented at the American Diabetes Association's (ADA) 82nd Scientific Sessions, adding to the robust body of data about Mounjaro for the treatment of adults with type 2 diabetes.
In the phase III AWARD-PEDS clinical trial from Eli Lilly, Trulicity (dulaglutide) (at 0.75 mg and 1.5 mg doses) led to superior A1C reductions at 26 weeks versus placebo in youth and adolescents (ages 10 to 17 years old) with type 2 diabetes inadequately controlled with diet and exercise, with or without metformin and/or basal insulin.
Novo Nordisk announced headline results from the main phases of ONWARDS 1 (52 weeks) and ONWARDS 6 (26 weeks) phase IIIa trials with once-weekly insulin icodec in type 2 diabetes.